HDYO-NZ members attended an update of the clinical trial which is testing the safety and effectiveness of drug RG6042 (Genentech/Roche) for patients with Huntington’s disease. Associate Professor Richard Roxburgh provided a summary of what the trial would look like for New Zealand, and what it means to be involved in this ground-breaking trial.